INTRODUCTION
============

Myotonic dystrophy (DM; also known as dystrophia myotonica), the most common form of muscular dystrophy in adults, is a progressively disabling disease that is inherited in an autosomal dominant manner, with anticipation (more severe phenotype and earlier onset from one generation to the next) and variable expressivity (symptoms vary among individuals) ([@b16-0040381]). The predominant symptoms are neuromuscular, including myotonia, muscular weakness and wasting. Other features of DM are cardiac conduction abnormalities, cognitive impairment, posterior cataract, frontal balding, testicular atrophy and insulin resistance. There are two forms of DM (DM1 and DM2), and these share several clinical symptoms and a similar molecular basis. DM1 and DM2 are both caused by unstable repeat expansions and their severity varies in proportion to the length of the repeat. The mutation underlying DM1 is a CTG repeat expansion in the 3′ untranslated region (UTR) of the *DMPK* gene ([@b7-0040381]; [@b9-0040381]; [@b14-0040381]; [@b27-0040381]), whereas DM2 is linked to a CCTG repeat in the first intron of the *ZNF9* (*CNBP*) gene ([@b24-0040381]). Both mutations are in UTRs; however, these regions are transcribed, resulting in mutant RNAs that are thought to exert an RNA trans-dominant effect ([@b32-0040381]). Previous studies have shown that mutant mRNAs containing the transcribed repeats are retained within the nuclei of DM1 and DM2 cells, where they bind and sequester specific RNA-binding proteins, including Muscleblind-like (MBNL) ([@b34-0040381]). It has been proposed that the sequestration of these proteins plays a key role in determining the classic features of DM ([@b32-0040381]), including alternative splicing abnormalities of specific transcripts ([@b36-0040381]; [@b37-0040381]; [@b10-0040381]; [@b30-0040381]). However, the functions of the MBNL genes are not completely understood.

MBNL proteins contain four zinc-finger domains of the CCCH type, and their homologue is required for muscle and photoreceptor development in *Drosophila* ([@b5-0040381]; [@b2-0040381]). In humans, there are three members of the MBNL family, MBNL1, MBNL2 and MBNL3, all of which have been shown to colocalize with the nuclear foci of expanded repeat transcripts in DM1 and DM2 cells and tissues ([@b12-0040381]; [@b29-0040381]; [@b13-0040381]). It is known that each of the MBNL proteins is expressed at different levels in different tissues, which points towards functional specialization. One of the proposed functions for MBNL proteins is that of regulating the alternative splicing patterns of particular transcripts at specific points during development ([@b17-0040381]; [@b22-0040381]). In the case of MBNL1, overexpression studies in a mouse model for DM support its role in DM pathogenesis, as it does in *Mbnl1* knockout mice ([@b19-0040381]; [@b20-0040381]). However, the specific functions of MBNL2 and its relevance to DM are not entirely elucidated.

The zebrafish (*Danio rerio*) is a powerful tool in which to study developmental biology, organogenesis and diseases of vertebrates, including, in recent years, humans ([@b11-0040381]; [@b4-0040381]). We employed a reverse genetics approach using antisense technology in order to determine the relevance of MBNL2 to DM and learn more about the function of this protein. As a result, we have produced and characterized an *mbnl2* knockdown model in zebrafish, which exhibits features of DM. We showed that loss of zebrafish *mbnl2* function produces splicing abnormalities and muscle defects, similar to those observed in DM. Moreover, *mbnl2* zebrafish morphants showed morphological abnormalities at the eye, heart and brain level, as well as defective somite patterning, suggesting that *mbnl2* plays an essential role during embryonic development.

RESULTS
=======

Expression pattern of zebrafish *mbnl2*
---------------------------------------

The annotation of the zebrafish gene family MBNL was carried out by sequencing cDNA clones and analysing the whole zebrafish genomic and expressed sequences available from public databases. Sequence comparison between human and zebrafish MBNL homologues, and the phylogenetic tree based on full-length alternatively spliced forms of the three members of this family, can be seen in supplementary material Fig. S1A,B.

To establish the spatial expression pattern of *mbnl2*, whole-mount in situ hybridization studies were conducted on zebrafish embryos at different stages of development, spanning from cleavage \[3--4 hours post-fertilization (hpf)\] to the hatching period (48--72 hpf). It was observed that the expression of *mbnl2* peaks during the segmentation period (10--24 hpf), with a strong bilateral signal detected at the mesencephalon and hindbrain level, in spinal cord neurons and in the caudal portion of the neural tube ([Fig. 1A--D](#f1-0040381){ref-type="fig"}). Later in development, during the pharyngula and hatching periods, the *mbnl2* signal was present in the pectoral fin bud, lens and telencephalon ([Fig. 1E](#f1-0040381){ref-type="fig"}). The use of a control sense probe allowed us to differentiate between the true positive signal and the background noise. A probe directed to *pax2a* was used with the purpose of highlighting the surrounding structures and delimiting the expression of *mbnl2* ([Fig. 1G--K](#f1-0040381){ref-type="fig"}). Pax2a is a well-known marker for the midbrain-hindbrain boundary, hindbrain, otic capsule and optic nerve ([Fig. 1I,J](#f1-0040381){ref-type="fig"}). Parallel and simultaneous detection of *mbnl2* and *pax2a* transcripts was carried out in a set of wild-type zebrafish at different stages of development. No overlap between the two probes was detected.

Knockdown of zebrafish *mbnl2* gene expression
----------------------------------------------

We used antisense technology in a loss-of-function approach to examine the in vivo role of *mbnl2*. Two translation-blocking morpholinos, MO-1 and MO-2, were designed to specifically target *mbnl2.* Their sequences were compared with those of *mbnl1* and *mbnl3* in order to assess potential cross-hybridization. Both morpholinos showed more than five mismatches with both transcripts ([Fig. 2A](#f2-0040381){ref-type="fig"}). Introducing morpholino MO-1 in zebrafish embryos resulted in a dose-dependent specific phenotype. The main abnormalities observed in the *mbnl2* morphants consisted of eye, brain and muscle defects, as well as abnormalities of cardiac structure and function ([Fig. 2B](#f2-0040381){ref-type="fig"}--M). Additionally, the movements of *mbnl2* morphants were restricted and uncoordinated. A second morpholino (MO-2), designed upstream to MO-1, mimicked this phenotype, but the effect was milder (data not shown). By contrast, injection of a standard control morpholino, with no target nor significant biological activity (Gene Tools), did not have any effect. Because of the lack of a suitable antibody it was not possible to demonstrate a reduction in the level of Mbnl2 protein following morpholino knockdown. Thus, we generated two further morpholinos, MO-3 and MO-4, to block the *mbnl2* splice sites flanking exon 1B, as shown in supplementary material Fig. S2. Embryos treated with MO-3 or MO-4 demonstrated the same phenotype as those treated with morpholino MO-1. Reverse transcriptase PCR (RT-PCR) analysis revealed that MO-4 treatment induced a mis-splicing event using an illegitimate splice site within exon 1B, resulting in the production of an anomalous isoform lacking the 3′ 42 bp of the exon, as shown in supplementary material Fig. S3. Translation of this isoform would result in an Mbnl2 protein lacking most of the first zinc finger. Supplementary material Fig. S4 shows the sequence of the deleted fragment.

![**Expression pattern of *mbnl2* in zebrafish.** During the segmentation period (A--D), the embryos display an *mbnl2*-positive signal in mesencephalon (1), at hindbrain level (2), in spinal cord neurons (3) and in neural tube (4). Panel B shows a schematic representation of the embryo in panel A, with the *mbnl2* signal symbolized in purple. (E) At 48 hpf, during the hatching period zebrafish *mbnl2* is also expressed in the lens (4). (F) The sense control probe allows us to differentiate between background and the true signal. (G) Single detection hybridization (*pax2a* + *mbnl2*) and (I) single detection of *pax2a* transcripts in wild-type zebrafish at 14 somites. Red arrows signal the position of *pax2a*-positive cells at the midbrain-hindbrain boundary and immature eye; red arrowheads show the position of the otic vesicles; purple arrows signal *mbnl2*-expressing cells. (J) At 48 hpf, *pax2a* is expressed in the midbrain-hindbrain boundary (a), hindbrain (b), otic capsule (c) and optic nerve (d). (K) During the same stage, *mbnl2* is expressed in the pectoral fin bud (e), lens (f), telencephalon (g) and epiphysis (h). The two signals do not overlap.](DMM004150F1){#f1-0040381}

![**The severity of the phenotype of *mbnl2* morphants varies in a dose-dependent manner.** (A) Alignment of the three zebrafish MBNL genes and morpholinos 1 (blue box) and 2 (green box), showing the specificity of both morpholinos for *mbnl2*. The initiation codon is boxed in red. (B--D) Control embryos (B) compared with mildly (C) and severely (D) affected morphant embryos at 51 hpf. (F,G) Developmental defects in *mbnl2* morphants include hypoplastic hypopigmented eyes and brain malformations; the hindbrain ventricle is swollen or enlarged, producing a convex appearance. (I,J) The hearts are hypoplastic and are elongated (I) or dilated (J), showing pericardial oedema, which results in bradycardia and failure. (K--M) The tails are twisted (L) or shortened (M), and the classic somite chevron-shape (K) is replaced by an oval or U shape (L, M). (B,E,H,K) Control embryos. Inset in E shows a normal wild-type eye.](DMM004150F2){#f2-0040381}

The caudal defects consisted of shortened and twisted tails. The severity of these malformations varied greatly, from a slight bending to a severe shortening. In moderately and severely affected embryos, the somite shape was altered, changing the classic chevron shape for a 'U' shape. Withdrawal movements in the *mbnl2* morphants ceased after a few seconds of gentle stimulation with a pipette tip, whereas, in the controls, there was a continuous avoidance response. The movements of the embryos were restricted and embryos showed an abnormal trembling pattern (see supplementary material Movies 1 and 2). At the eye level, the morphants presented asymmetric defects, which varied from mild to severe unilateral hypoplasia and hypopigmentation. The normal morphology was lost at the midbrain level in moderate-to-severe morphants. In mild morphants, the hindbrain ventricle seemed swollen or enlarged, giving the head a convex appearance. The hearts of the morphants were hypoplastic and became elongated and/or dilated after 48 hpf. Pericardial oedema was of common occurrence, and in some cases pools of static blood formed in the surrounding area. The cardiac deformities caused progressive malfunctioning of this organ, with heart beating slowing down and finally stopping.

In order to determine whether there is compensatory expression of the paralogues following *mbnl2* knockdown, we performed quantitative RT-PCR analysis to determine the levels of expression of *mbnl1* and *mbnl3*. Supplementary material Fig. S5 shows that there is no significant change in the levels of *mbnl1* or *mbnl3* following knockdown of *mbnl2*.

Morpholinos sometimes induce off-target effects, which are caused by upregulation of p53 and subsequent apoptosis. Injection of a morpholino against p53 can alleviate these effects and facilitate the observation of true phenotypes. When MO-p53 was co-injected with the *mbnl2* MO-1 morpholino, the level of neural death was reduced, although a mild brain phenotype was still observed. The other defects -- shortened twisted tails, hypoplastic hearts and pericardial oedema -- all remained unchanged.

Deficiency of Mbnl2 causes skeletal and cardiac muscle abnormalities
--------------------------------------------------------------------

We assessed the effect of *mbnl2* knockdown on muscle development and fibre type specification by light microscopy, transmission electron microscopy (TEM) and immunohistochemistry assays. Histological analysis of sections stained with toluidine blue was carried out on specimens at 52 hpf ([Fig. 3A,B](#f3-0040381){ref-type="fig"}). The somite chevron shape expected at this stage of development was lost in the entire set of *mbnl2* morphant embryos examined, which showed an abnormally irregular or 'U' somite shape. A decreased number of muscle fibres, which made the nuclei appear more prominent, was also noticed in *mbnl2* morphants when compared with controls. Moreover, the diminished muscle fibres of the morphants were abnormally organized, appearing short and irregular. These fibres lacked the parallel tight alignment seen in the muscle of controls and were scattered in the somitic compartment.

Previous work has revealed that DM1 skeletal muscle shows a characteristic type 1 (slow) fibre hypoplasia, and DM2 a type 2 (fast) fibre hypoplasia ([@b8-0040381]; [@b41-0040381]; [@b42-0040381]; [@b38-0040381]). To investigate whether the hypoplasia in the *mbnl2* morphants occurred at the expense of a particular fibre type, slow and fast sarcomeric myosins were targeted with antibodies S58 and MF20. S58 monoclonal IgA is specific for slow muscle fibre myosin heavy chain (MHC) isoforms ([@b33-0040381]). MF20 is an IgG2b monoclonal antibody, which reacts with all sarcomeric myosins ([@b3-0040381]). It was found that the amount of both fast and slow fibres was significantly reduced, and their distribution pattern was altered ([Fig. 3C,D](#f3-0040381){ref-type="fig"}). As shown in [Fig. 3](#f3-0040381){ref-type="fig"}, control embryos at 52 hpf showed the expected normal distribution of muscle fibres, with the slow fibres forming an even layer in the periphery (yellowish green), and the rest of the fibres (red) organized towards the centre. In transverse sections of 52-hpf *mbnl2* morphants, both slow and fast muscle fibres were disorganized and scattered, and the outer layer of slow muscle was discontinuous, alternating with fast fibres and non-muscle DAPI-positive tissue. We performed fibre counting in confocal micrographs from three *mbnl2* morphant embryos and found no difference in the proportion of fast and slow type fibres when compared with three age-paired controls. Additionally, we confirmed an overall reduction of 37.7% on average in the number of skeletal muscle fibres in the morphants ([Table 1](#t1-0040381){ref-type="table"}). Analysis of muscle ultrastructure by TEM was performed on the morphants and controls at the skeletal muscle and heart level ([Fig. 3E--L](#f3-0040381){ref-type="fig"}). Sections of skeletal muscle of normal embryos showed the expected ultrastructure with well-aligned myofibrils and their Z-bands being regularly stacked. All the sarcomeric elements and triads were easily identifiable. By contrast, in age-paired *mbnl2* morphants, there were fewer fibres compared with in the controls, and the myofibrils were scattered and disorganized, running in different directions. Some of the Z-bands were condensed, and the Z-bands of adjacent myofibrils were not in register. Often, it was observed that the H-zone and the I-band were absent from morphant sarcomeres, giving the impression of muscle hypercontraction. Less frequently, in some of the morphants the sarcoplasmic reticulum was disorganized, often lacking the well-ordered triads evident in the control embryos. At the heart level, light microscopy analysis of the *mbnl2* morphant revealed dilated heart cavities, which were smaller in size than those of sibling controls ([Fig. 3G,H](#f3-0040381){ref-type="fig"}). TEM analysis of heart tissue from the morphants showed streaming and condensation of the Z-bands in the sarcomere. Additionally, the H-zone and I-band were not recognizable in most of the sarcomeres, and myofibril disorganization and disintegration were also seen ([Fig. 3I--L](#f3-0040381){ref-type="fig"}). Although there was obvious evidence of muscle disruption, the underlying cause was not clear. To determine whether this disruption is due to a failure of muscle differentiation, we examined the expression of the muscle marker MyoD. Preliminary analysis (supplementary material Fig. S6) revealed no gross level change to the distribution of MyoD expression, suggesting that the early pattern of muscle formation is maintained in *mbnl2* morphants. However, MyoD expression was slightly reduced in the more anterior somites of the morphants at 18 hpf compared with wild-type embryos (supplementary material Fig. S6C,D). This difference was more pronounced in 24-hpf embryos (supplementary material Fig. S6E-H). Further work will be required to assess whether these differences represent primary changes or whether they are secondary effects due to other morphological constraints.

###### 

Analysis of the proportion of low and fast type fibres

![](DMM004150T1)

*mbnl2* morphants display alternative splicing defects of specific transcripts
------------------------------------------------------------------------------

Dysregulation of alternative splicing of specific transcripts, including cardiac troponin T (*TNNT2*) and the muscle chloride channel (*CLCN1*), are associated with DM ([@b36-0040381]; [@b10-0040381]; [@b30-0040381]). We examined the effect of knocking down the function of *mbnl2* on the alternative splicing pattern of transcripts of orthologous zebrafish genes. The genomic organization and alternative splicing pattern of zebrafish *clcn1* and *scn4ab* (voltage-gated sodium channel type IV, alpha subunit) were established by sequence analysis, as described for the MBNL genes. The exon layout and splicing events in zebrafish *tnnt2* have been described elsewhere ([@b18-0040381]).

![**Histological and molecular analyses of skeletal and cardiac muscle of *mbnl2* morphants.** (A,B) In longitudinal sections through the muscles of the tail of zebrafish embryos at 40× magnification, the controls (A) show a normal somite chevron shape and fibre alignment, whereas the *mbnl2* morphants (B) show an abnormal somite shape, and misaligned muscle fibres, which appear scattered in the somitic compartment. (C,D) Immunofluorescence staining with S58 and MF20 antibodies in transverse sections of 52-hpf zebrafish embryos shows slow (S58 positive; yellowish green) and fast (S58 negative, MF20 positive; red) fibre distribution in somitic muscles of control embryos (C) compared with *mbnl2* morphants (D); DAPI was used as a blue nuclear counterstain. (E) Electron micrographs of skeletal muscle from 52-hpf control zebrafish show that the myofibrils are aligned, their Z-bands are regularly stacked (green square bracket), and H-zones (H) and I-bands (I) are clearly identifiable. (F) *mbnl2* morphants show misaligned myofibrils, Z-bands with irregular width, disorganized sarcoplasmic reticulum (\*) and short sarcomeres resulting in loss of H-zones and I-bands (arrowheads). (G) In normal zebrafish hearts (20× magnification), the blood cells fill in the atrial cavity (a). (H) By contrast, the heart in *mbnl2* morphants is dilated and empty; black arrowhead points to the myocardium and white arrowhead to the endocardium. (I--L) Electron micrographs of sections through the hearts of zebrafish embryos. Tightly organized myofibril bundles can be seen in transverse sections of wild-type controls (I), whereas dispersed myofibrils (arrows) are apparent in the *mbnl2* morphant embryos (J). (K) Longitudinal sections showing normal sarcomeric organization of the Z-line (z), H-zone (h), I-band (I) and M-line (m) in controls. (L) The myofibrils are less organized and sometimes disrupted (arrow) in the morphants, condensation of the Z-bands in the sarcomere can be seen (\*), and H-zone and I-band are not recognizable in severe cases.](DMM004150F3){#f3-0040381}

Alternatively spliced variants of *tnnt2* were amplified from *mbnl2* morphants and age-paired control embryos at 51 hpf by RT-PCR. When using primers located in exons 1 and 8, two main bands of 318 bp and 282 bp were revealed ([Fig. 4A](#f4-0040381){ref-type="fig"}). Both products were detected in the controls, but only the 318 bp product was present in the morphants. Direct sequencing of the purified products showed that they contained variants of *tnnt2* in which exons 4 and 6 are alternatively spliced. It was confirmed that the 318 bp product includes alternatively spliced exon 6, whereas the 282 bp product excludes it. To learn more about the splicing of *tnnt2* transcripts during zebrafish development, we analyzed pools of embryos at different stages. We found that, during the earliest stages (18 somites and 24 hpf), the embryos express the 318 bp transcript. By contrast, later in development (51 hpf, 72 hpf and adults) both of the isoforms were clearly expressed ([Fig. 4B](#f4-0040381){ref-type="fig"}).

![**Expression of alternatively spliced transcripts in *mbnl2* morphants.** (A) RT-PCR analysis using primers tnnt2F and tnnt2R3 (arrows) yields two main bands of 318 bp and 282 bp in control embryos ('C'), whereas the 282 bp product is not detectable in the morphants (MO). Boxes depict the exon content of each product after sequencing. Exons 4 (green) and 6 (yellow) are alternatively spliced. (B) The normal *tnnt2* alternative splicing pattern is shown at different developmental stages. RT-PCR analysis of control embryos at the 18-somite stage (1) and 24 hpf (2) shows the expression of a 318 bp product. 51 hpf (3), 76 hpf (4) and adult (5) controls express both isoforms, 318 bp and 282 bp. (C) RT-PCR analysis of *clcn1*. Primers clcn1-134F and clcn1-87R (arrows) produce two bands, one of 588 bp (including exon 18a) and one of 555 bp (excluding exon 18a), which are expressed at a ratio of 1:1.2 in control embryos, whereas, in the *mbnl2* morphants, the 555 bp product is the predominant form, shifting the ratio to 1:1.98. Differences in exon content are shown in the boxes. Exon 18a (red) is alternatively spliced and encodes amino acids FTKLSPAGGVK.](DMM004150F4){#f4-0040381}

The expression of *clcn1* isoforms was also analyzed by RT-PCR using a set of primers designed to cover different exon splicing combinations. [Fig. 4C](#f4-0040381){ref-type="fig"} shows that primers located in exons 15 and 21 produced two bands of 588 bp and 555 bp. These products were expressed at a ratio of 1:1.2 in control embryos. However, in the *mbnl2* morphants there was a shift in the ratio of the two forms to 1:1.98 due to increased expression of the 555 bp isoform. After sequencing three independently amplified RT-PCR fragments, from both controls and morphants, it was found that the two products differ in the inclusion or exclusion of a newly identified 33 bp exon (18a), which was predicted to encode 11 amino acids (FTKLSPAGGVK) located in between the first and second cytoplasmic CBS domains, at the C-terminal end of the Clcn1 protein. A similar shift in the ratio of splice forms was observed in embryos treated with the other *mbnl2*-directed morpholinos. A further example of the skewed ratio of *clcn1* isoforms is shown in supplementary material Fig. S7 following treatment with MO-4.

To determine whether the alternative splicing changes observed in the *mbnl2* morphants represented specific events or global changes to alternative splicing, we analyzed the expression of zebrafish s*cn4ab* in control and morphant embryos (supplementary material Fig. S8A,B). No difference in size or exon content for *scn4ab* transcripts was detected when using multiple primer combinations, restriction enzyme digests and sequencing (supplementary material Fig. S8C and Table S1). These results are comparable to those in DM patients, in whom the alternative splicing of the homologous gene is also unaltered ([@b10-0040381]).

The *mbnl2* morphant phenotype can be rescued by *mbnl2* and *MBNL2*
--------------------------------------------------------------------

To further assess the specificity of the *mbnl2* morpholino effects, we performed rescue experiments with full-length capped *mbnl2* mRNA co-injected with morpholino MO-1 ([Fig. 5](#f5-0040381){ref-type="fig"} and [Table 2](#t2-0040381){ref-type="table"}). The amount of MO-1 injected was the optimum for producing a moderate-to-severe phenotype with a low mortality rate (4.28 ng). The dosage of *mbnl2* mRNA was titrated to obtain the highest numbers of rescued embryos without the synthetic mRNA toxic effects. It was found that 150 pg mRNA was the most effective rescue dose. As a further control we also co-injected embryos with MO-1 and unrelated RNA, Xenopus elongation factor 1α, to ensure that the injected RNA did not affect morpholino activity non-specifically.

###### 

Rescue of *mbnl2* morphant phenotype

![](DMM004150T2)

![**The *mbnl2* morphant phenotype can be rescued by *mbnl2* and *MBNL2* mRNAs, in a dose-dependent manner.** (A) The phenotype induced by MO-1 is rescued by co-injection with *mbnl2* mRNA. The histogram shows the frequency of the observed phenotype after injection of 4.28 ng MO-1 or the same amount of MO-2 (*n*=100, from five independent experiments). The percentage of affected embryos is significantly reduced when 150 pg *mbnl2* mRNA is co-injected with 4.28 ng MO-1. (B,C) The completely rescued embryos (B) are indistinguishable from the controls (C). (D) The partially rescued embryos show a mild phenotype consisting of the presence of slight eye pigmentation defects, minor heart hypoplasia, mild spinal defects, and a head that is protuberant at the fourth ventricle level of the hindbrain. (E,F) The normal splicing pattern of *tnnt2* (E) and *clcn1* (F) is restored by co-injection of MO-1 with *mbnl2* mRNA. The ratio of the upper and lower band is 1:2 in the morphants (MO), whereas, in controls (CT), it is 1:1.46, and is 1:1.34 in the rescued embryos (R). When co-injecting the human homologue, 75 pg of *MBNL2* mRNA is the most effective dose in compensating the phenotype induced by MO-1 ([Table 2](#t2-0040381){ref-type="table"}).](DMM004150F5){#f5-0040381}

A complete rescue of the external phenotype was achieved in 64% of treated embryos, and a partial rescue was obtained in 32% of embryos ([Fig. 5A--D](#f5-0040381){ref-type="fig"} and [Table 2](#t2-0040381){ref-type="table"}). Furthermore, recovery of the wild-type splicing pattern of *tnnt2* and *clcn1* transcripts was observed in rescued embryos ([Fig. 5E,F](#f5-0040381){ref-type="fig"}). In addition, we tested the ability of the human *mbnl2* homologue, *MBNL2*, to rescue the *mbnl2* morphant phenotype: when using 75 pg of *MBNL2* mRNA plus 4.28 ng of MO-1, up to 55% of embryos were completely rescued plus 24% were partially rescued ([Table 2](#t2-0040381){ref-type="table"}). The unrelated *Xenopus* RNA had no effect on the mutant phenotype. These results suggest that the mechanisms involved in MBNL2-dependent alternative splicing have been conserved throughout vertebrate evolution.

DISCUSSION
==========

Role of MBNL proteins in DM
---------------------------

At present, there is substantial evidence to support an RNA-mediated pathogenic mechanism for DM1 and DM2, in which pathogenic RNAs accumulate within the nuclei of DM cells, where they sequester specific RNA-binding proteins such as MBNL2, causing disruptions to different cellular processes. Currently, the functions of the three MBNL genes are not completely understood. It has been suggested that MBNL proteins participate in regulating the alternative splicing of specific transcripts such as insulin receptor (IR) and TNNT2 ([@b17-0040381]). Interestingly, an additional function has been suggested involving MBNL2 in the localization of the mRNA of transmembrane protein integrin α3 to focal adhesion sites ([@b1-0040381]).

A variety of animal models have been produced to gain insight into the molecular basis of DM. However, none of them have recapitulated all of the signs and symptoms of this disease, reinforcing the idea that DM is a disease with an unconventional complex pathophysiology. Nonetheless, different lessons can be learned from each model. In particular, *Mbnl1* knockout mice show DM features including myotonia, abnormal central nuclei in myofibres, ocular cataracts and splicing alterations of *Clcn1*, *Tnnt2* and fast skeletal muscle troponin T (*Tnnt3*) ([@b19-0040381]). Some of these defects, namely myotonia and chloride channel splicing abnormalities, are shared by a recently published knockout model in mice for *Mbnl2* ([@b15-0040381]), produced by disruption of the protein at the beginning of the second zinc finger. However, a similar knockout model, in which mice were generated by a gene trap vector targeted to intron 4, in which the first two zinc fingers of *Mbnl2* are conserved, shows no specific phenotype ([@b23-0040381]). We observe a consistent phenotype with both translation-blocking and splice-blocking morpholinos, which have a different mechanism of action. Our results suggest that Mbnl2 deficiency in zebrafish produces features more similar to those reported in the mouse by Hao et al. ([@b15-0040381]). At the muscle level, apart from the obvious differences in muscle organization between the two species, increased heterogeneity and an overall reduction in skeletal muscle fibres was reported in both. Similarly, these authors also report a modest increase in the presence of an alternative RNA splice form of *Clcn1*, and normal splicing of other transcripts tested, whereas *clcn1* splicing defects are more prominent in our zebrafish morphants and are accompanied by notable alterations of *tnnt2* (not examined in the mouse model). The absence of reported developmental defects in the *Mbnl2*-deficient mice might be due to evolutionary divergence. Analysis of *muscleblind* (*Mbl*)-deficient flies reveals developmental defects of the eye and muscle, with disorganization of sarcomeres, muscle contraction and failure to survive beyond the first instar larva stage. This demonstrates that a higher deficiency of Muscleblind function can affect the development of specific organs in other species.

*mbnl2*-deficient zebrafish exhibit features of DM
--------------------------------------------------

We have identified and characterized three MBNL genes in zebrafish as a counterpart of those in humans. Our data is consistent with the recently published findings of another research group ([@b25-0040381]). In order to further dissect the function of *mbnl2*, we generated a zebrafish model using antisense technology in a loss-of-function approach. The antisense morpholino molecule was designed to block the translation of the entire *mbnl2* mRNA. The phenotype obtained in *mbnl2* morphants was demonstrated to be specific and dose dependent, and included morphological abnormalities at the eye and skeletal muscle levels. Our results were consistent with those previously reported in *Drosophila*, in which a role in photoreceptor and muscle development was established ([@b5-0040381]; [@b2-0040381]). Moreover, brain and cardiac defects were also part of the phenotype of *mbnl2* morphants. Whether these were due to unknown activity of Mbnl2 during development in vertebrates, or to a secondary effect on downstream genes, remains to be elucidated.

Dysregulation of alternative splicing of specific transcripts, including *TNNT2* and *CLCN1*, is a key feature of DM and is thought to contribute to the production of cardiac abnormalities (*TNNT2*) and myotonia (*CLCN1*) in DM patients ([@b36-0040381]; [@b10-0040381]; [@b30-0040381]). Likewise, we found that *tnnt2* and *clcn1* alternative splicing patterns are disrupted in *mbnl2* morphants, which show cardiac and skeletal muscle abnormalities. Interestingly, the analysis of *scn4ab*, another ion channel linked to myotonia, showed no splicing alterations, consistent with the absence of such changes in DM patients ([@b31-0040381]). In the case of *clcn1*, we showed the presence of two distinctive isoforms expressed in almost equal proportions in the wild type, whereas *mbnl2* morphants were found to preferentially express the 555 bp form. Additionally, we established that the splicing pattern of *tnnt2* shown by *mbnl2* morphants was similar to that observed in fish during earlier developmental stages. In a similar manner, DM adult patients express a *TNNT2* isoform that includes an exon preferentially expressed in embryonic tissue but not in adult controls ([@b36-0040381]). These observations support a role for MBNL2 as a regulator of developmentally programmed alternative splicing of specific transcripts. Our results demonstrate that the loss of *mbnl2* function is sufficient to produce alternative splicing defects in transcripts of particular genes that are involved in DM.

Originally, myopathic changes in DM muscle, including fibre size variation, seemed to be similar in both DM1 and DM2 ([@b38-0040381]). However, some distinction emerged when using immunohistochemistry to assess fibre type differentiation. DM1 muscle exhibited a characteristic type 1 (slow) fibre atrophy, in contrast with type 2 (fast) fibre atrophy in DM2 ([@b8-0040381]; [@b42-0040381]). We set out to investigate whether the *mbnl2*-deficient fish showed any muscle alteration parallel to those observed in DM. First, it was observed that the *mbnl2* morphants displayed an abnormal somite shape and overall reduction of the number of muscle fibres. Immunohistological studies were used to assess fibre type proportion, which confirmed that the number of both fast and slow fibres was significantly reduced, and their distribution pattern was altered, in *mbnl2* morphants. In addition, electron microscopic studies on skeletal and cardiac muscle showed impaired alignment of myofibrils, abnormal Z-bands and disorganization of the sarcoplasmic reticulum, all of which are features shared with DM muscle ([@b21-0040381]; [@b26-0040381]).

In summary, our study provides broader insight into the function of MBNL2 as a splicing regulator and as a major participant during muscle, heart, eye and brain development. We showed that key features of DM are replicated in our zebrafish *mbnl2* knockdown model, with ultrastructural and molecular parallels. Taken together, the results presented herein support the idea that the sequestration of MBNL2 is an important determinant of muscle pathophysiology and splicing disruption in DM, which must be considered when developing therapeutic approaches for this condition.

In view of the accessibility of the zebrafish as a model for developmental studies, our data provides the starting point for experiments to dissect the molecular pathway producing muscle weakness and wasting in DM.

METHODS
=======

Characterization of MBNL genes in zebrafish
-------------------------------------------

Human MBNL nucleotide and protein sequences were obtained from public databases (NCBI, ENSEMBL, ZFIN) and used to retrieve ESTs and mRNA sequences from zebrafish. ESTs containing a full open reading frame were computationally predicted based on homology with known genes. The corresponding cDNA clones were obtained from MRC geneservices and RZPD, and were fully sequenced by primer walking. Alignments and phylogenetic analyses were carried out using BLAST and ClustalW tools, and BioEdit and TreeView software. The phylogenetic tree was constructed by the neighbour-joining method ([@b35-0040381]). The zebrafish genomic sequences used to annotate the MBNL genes correspond to Zv4 and Zv5 assemblies from the *Danio rerio* Sequencing Project.

Microinjection of zebrafish embryos
-----------------------------------

Zebrafish stocks were maintained as described ([@b43-0040381]). Two translation blocking morpholino oligonucleotides were designed for *mbnl2* and manufactured by Gene Tools: MO-1: 5′-TAAAGCCATAGTTGTGTTGTGAATG-3′ and MO-2: 5′-GTTTGTGTGTTGCTGTACTTTTGAG-3′, which was designed upstream of MO-1. Wild-type zebrafish embryos at the one- to four-cell stage were microinjected with 1 nl of titrated doses of morpholino to determine the efficiency/toxicity window. Siblings from the same pool of morpholino-injected embryos served as non-injected controls. Additionally, a standard control morpholino, 5′-CCTCTTACCTCAGTTACAATTTATA-3′ (Gene Tools), was injected into a group of control embryos. Full-length capped *mbnl2* and *MBNL2* mRNAs were synthesized using the mMessage mMachine kit (Ambion) according to the manufacturer's instructions, and cleaned up using Ambion's MEGAclear kit. Titrated doses of the resulting capped mRNA were injected alone and in conjunction with either control or MO-1 morpholinos. All experimental procedures complied with institutional and national animal welfare laws, guidelines and policies.

Whole-mount in situ hybridization
---------------------------------

Zebrafish *mbnl2* plasmid DNA was linearized with *Eco*RI-*Xho*I and then purified by phenol/chloroform/isoamyl alcohol extraction and subsequent ethanol precipitation. A *pax2a* antisense probe was produced after linearizing the corresponding plasmid cDNA with *Bam*HI as described elsewhere ([@b6-0040381]; [@b28-0040381]). Sense and antisense riboprobes were obtained by in vitro transcription of 0.2 pmol of linear plasmid DNA. Reactions were set up with 10--40 U of the corresponding (SP6, T7 or T3) RNA polymerase (Roche), 10× concentrated transcription buffer \[400 mM Tris-HCl (pH 8.0; 20°C), 60 mM MgCl~2~, 100 mM dithiothreitol (DTT), 20 mM spermidine\], 20 U RNase inhibitor (RNasin, Promega), 10 mM ATP, 10 mM CTP, 10 mM GTP, 6.5 mM UTP, 3.5 mM DIG-UTP and sterile distilled water to make a total volume of 20 μl. The reaction was incubated overnight at 37°C. The resulting DIG-labelled RNA was precipitated with 0.3M NH~4~Ac and ethanol, and was resuspended in DEPC-treated water. The in situ hybridization process was carried out as described ([@b40-0040381]). The embryos were mounted in glycerol and the results registered using a Nikon digital camera attached to a SMZ1000 Nikon microscope with a cold light source (Photonic). The images were processed with ACT-2U (Nikon) imaging software.

Immunohistochemistry
--------------------

After harvesting at different developmental stages, the fish embryos were immersed in 30% sucrose for 60 minutes and frozen down in OCT (RA Lamb) using liquid nitrogen cooled isopentane. 20-μm sections were cut on a cryostat (Microm HM505E) and collected on 3-aminopropyltriethoxysilane (APES)-coated glass slides. The sections were post fixed with 0.5% paraformaldehyde (PFA) for 3 minutes, washed three times in PBS, and permeabilized by incubation with 0.15% Triton X-100 (Promega) for 10 minutes. Blocking was carried out by incubation with 5% bovine serum albumin (BSA; Roche) for 30 minutes. Antigens of interest were labelled first by incubating with S58 anti-slow MHC primary antibody \[DSHB (Developmental Studies Hybridoma Bank, University of Iowa, NICHD); diluted 1:50\] and visualized by incubating with anti-mouse Alexa Fluor 488 secondary antibody (Invitrogen; diluted 1:300), then by incubating with MF20 anti-sarcomere myosin primary antibody (DSHB; diluted 1:50) and visualized by incubating with anti-mouse Alexa Fluor 555 secondary antibody (Invitrogen; diluted 1:300). For the fibre migration study, the F59 antibody (DSHB) was used at a dilution of 1:50 and visualized with Alexa Fluor 555. Sections were mounted and coverslips applied with VECTORSHIELD containing DAPI (Vector Labs). Sections were analyzed and photographed using fluorescent microscopy (Nikon Optiphot-2 microscope with Spot Insight imaging system). Further imaging was performed at room temperature on a confocal laser-scanning microscope (Zeiss LSMuv META Combi confocal on a Zeiss Axiovert 100 microscope). Stacks were acquired and all the images were processed and analyzed using Zeiss LSM software.

Electron microscopy
-------------------

Selected zebrafish embryos were dechorionated manually and killed using an overdose of anaesthetic ethyl *m*-aminobenzoate tricane methane sulfonate (MS-222; Sigma). The embryos were then fixed in 3% glutaraldehyde in PBS for a minimum of 1 hour. Secondary fixation was achieved by incubation in 1% aqueous osmium tetroxide (OsO~4~) for 1 hour. Subsequently, the fish were rinsed in water and dehydrated in an acetone series (10 minutes each in 50%, 70%, 80%, 90%, 95%, 100% and dried), infiltrated with 1:1 Araldite:acetone overnight, embedded in Araldite (Agar Scientific) and finally polymerized on oven at 50°C. In order to ensure adequate orientation of the specimens, most of the fish were cut into two regions, thorax and tail. These pieces and further sections cut from the tail were embedded separately. Semi-thin sections (0.5 μm) were first cut using an Ultracut E microtome (Reichert-Jung), stained with toluidine blue and examined by light microscopy to observe the morphology. Ultra-thin sections of about 100 nm were cut and then collected on a copper grid and stained with 2% uranyl acetate and Reynold's lead citrate. The sections were examined using a JEOL 1200 electron microscope and images recorded at various magnifications between 5000× and 20,000× on Kodak SO-163 electron microscope film.

RNA extraction and RT-PCR
-------------------------

Sample homogenates were obtained by grinding 20--25 mg of zebrafish embryo samples in lysis buffer (QIAGEN) using a Polytron blender. Total RNA was extracted from pools of zebrafish embryos using the QIAGEN RNeasy kit, according to the manufacturer's recommendations. The first-strand cDNA was synthesized from 1--2 μg of total RNA using anchored oligo-dT for *tnnt2*, and a mix of anchored oligo-dT 1:3 random hexamers in the case of *clcn1* and *scn4ab*. A blend of AMV and MMuLV reverse transcriptases, 5× buffer (ABgene), 5 nm dNTPs and RNase inhibitor was then added, and the samples were incubated at 55.6--59°C for 90 minutes, followed by 10 minutes at 75°C for enzyme inactivation. Different sets of primers were designed according to the alternative splicing analysis of each transcript. Zebrafish *tnnt2* was amplified by RT-PCR with primers published elsewhere ([@b18-0040381]). Zebrafish *clcn1* and *scn4ab* were amplified using primers listed in supplementary material Tables S2 and S3. PCR amplification of reverse transcribed products was carried out in 25 μl reactions, containing 200 nM primers, 100--250 ng cDNA, 350 μM dNTPs, 2.25 mM MgCl~2~ and 1.25U Taq Extensor Hi-fidelity DNA polymerase (ABgene). The amplification cycles were performed as follows: 94°C for 2 minutes, with 25--30 cycles of 94°C for 10 seconds, 50--60°C for 10 seconds and 68°C for 1 minute followed by an extension cycle of 68°C for 5 minutes. RT-PCR products were resolved by electrophoresis on 1.5--2.5% agarose gels and visualized with ethidium bromide. The gels were scanned and the density of the bands was quantified using ImageJ software (Wayne Rasband, NIH). Percentage exon inclusion was calculated as: \[exon inclusion band/(exon inclusion band + exon exclusion band)\] × 100. All the samples were analyzed in triplicate.

Restriction digest assay
------------------------

Restriction enzyme digests were performed on purified RT-PCR products produced with primers for zebrafish *scn4ab*. The following restriction enzymes were used: *Nde*I + *Bcl*I, *BamH*I + *Ssp*I, *EcoR*I + *Xba*I, *Ssp*I + *Bmr*I (New England Biolabs). Reactions of 10 μl were set up with 1--3 U of restriction enzyme per μg DNA with 1μl 10× buffer and 0.1 μl 100× BSA (10 mg/ml), and were incubated overnight at the corresponding temperature according to the manufacturer's instructions.

Sequencing analysis
-------------------

RT-PCR and restriction digestion products from *tnnt2* and *scn4ab* were excised from agarose gels and purified using the QIAquick PCR purification kit (QIAGEN) for direct sequencing. Additionally, *clcn1* RT-PCR products were cloned into T-easy vector (Promega). Sequencing reactions were set up using Big Dye Terminator (Applied Biosystems) and visualized on an ABI 3100 Genetic Analyser (Applied Biosystems). Gap4 and Pregap4 programs from the Staden Package ([@b39-0040381]) (MRC Laboratory of Molecular Biology, Cambridge, UK) were used for multiple DNA sequence assembly.

Annotation of zebrafish gene family MBNL
----------------------------------------

The corresponding human and murine transcripts and proteins were compared against the whole zebrafish genome and expressed sequences available from public databases. Zebrafish ESTs and mRNAs that exhibited high similarity with the query sequences were selected. The cDNA clones corresponding to ESTs with the highest scores were retrieved, cultured, sequenced by primer walking and analyzed. Three different populations of cDNA were characterized, corresponding to alternatively spliced isoforms derived from three orthologous MBNL genes, which showed high identity with their human counterparts. The four distinctive CCCH zinc-finger domains, organized in two pairs (CX~7~CX~6~CX~3~H and CX~7~CX~4~CX~3~H), as well as the regions enriched in alanine and proline, were identified in the three zebrafish MBNL proteins. The percentage of identity between human and zebrafish MBNL homologues was 79.41% for MBNL1, 80% for MBNL2 and 71.91% for MBNL3, at a protein level. The highest level of identity, near 100%, was found at the four zinc-finger domains level, whereas the highest divergence was found in the sequence located between and after the two sets of zinc fingers (supplementary material Fig. S1A). When other vertebrate and non-vertebrate species were included in the alignment, a similar conservation pattern was observed (data not shown). To examine the evolutionary relationship between zebrafish and human MBNL proteins, we constructed a phylogenetic tree based on full-length alternatively spliced forms of the three members of this family (supplementary material Fig. S1B). Zebrafish *mbnl1*, *mbnl2* and *mbnl3* clustered with their human counterparts into three distinct monophyletic groups. Orthologous relationships between zebrafish and humans in the three branches were supported.

To determine whether these observations were biased by sequence variation in the highly divergent regions, a phylogenetic tree based on partial sequences that omitted such regions was constructed. Nevertheless, there was no significant difference in the tree topology. During the preparation of this manuscript, an independent group reported an annotation for the zebrafish MBNL family of genes ([@b25-0040381]). Our annotation shows slight differences with those of Liu et al.
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Primers used in this study
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RNA purification and reverse transcription
------------------------------------------

Total RNA was isolated from zebrafish embryos at 51 hpf in batches of 50--80 embryos, using a QIAGEN RNeasy Fibrous Tissue kit. First-strand cDNA was synthesized using 1 μg of total RNA with M-MuLV reverse transcriptase (Thermo Scientific) in a final volume of 25 μl including 1× RT buffer, 1 mM dNTPs, 20 units of RNase inhibitor and 1 μl of random hexamers (400 ng/μl) made up with DEPC water. The reaction mixture was incubated at 37°C for 2 hours.

Real time PCR
-------------

Primers for the real-time assay were designed using the Universal Probe Library Assay design centre software on the Roche-Applied-Science website (see [Table 3](#t3-0040381){ref-type="table"}).

The real-time PCR assay was performed on an ABI 7500 Fast Real Time PCR system using a SensiMix Real-Time kit according to the manufacturers' instructions. Amplification conditions were 95°C (10 minutes), followed by 40 cycles of 95°C (15 seconds) and 60°C (60 seconds). β-actin1 and β-actin2 were used as reference gene controls and a no-template control was also included. Each sample was amplified in triplicate and three biological replicates were used. A standard curve of four dilution points (in steps of fivefold) was generated for the wild-type cDNA and each test cDNA was diluted 1:5. The relative expression of each gene was calculated using the ABI 7500 software to produce plots illustrating relative fold changes in respect to sample.

Additional primer sequences used were: F3 + R7 Primers, F3 5′-CAAACGCGCAGACTATTTCA-3′ and R7 5′-TCTGCTGG-ATGAGGTTGTTG-3′.
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TRANSLATIONAL IMPACTClinical issueMyotonic dystrophy (DM) is the most common adult muscular dystrophy, affecting ∼1 in 8000 people. Clinical symptoms include progressive muscle weakness and wasting, predominantly in the eye, brain and endocrine system. DM exists in two forms: DM1, which is caused by a triplet repeat expansion in the *DMPK* gene, and DM2, which is caused by a tetranucleotide repeat expansion in the *ZNF9* gene. In both forms of the disease, repeat-expanded transcripts do not get processed properly and remain trapped in the nuclei of DM patient cells, where they associate with RNA-binding factors including muscleblind-like (MBNL) proteins. It is thought that the subsequent sequestration of MBNL proteins disrupts proper regulation of alternative splicing of other transcripts and is central to the pathology of DM. The three human MBNL proteins have different expression levels and tissue specificities, suggesting specialized functions. Thus far, studies addressing the mechanisms underlying DM are relatively limited and have focused mainly on the involvement of MBNL1.ResultsIn this paper, the authors investigate the involvement of MBNL2 in the pathology of DM by creating a zebrafish morphant of the homologous *mbnl2* gene. They first establish that zebrafish *mbnl2* is expressed in muscle and brain during early developmental stages. Knockdown of *mbnl2* expression in the zebrafish embryo leads to a distinct phenotype involving skeletal and cardiac muscle abnormalities that resemble some of the defects observed in DM patients. Furthermore, knockdown of *mbnl2* alone was sufficient to disrupt alternative splicing of RNA transcripts that are also abnormally spliced in DM patients. The authors also demonstrate the use of the zebrafish model for the detailed study of muscle fibre type distribution: compared with wild-type fish, the *mbnl2* morphant showed abnormalities in the number of both fast and slow muscle fibres, which is differentially affected in DM1 and DM2.Implications and future directionsThis work suggests a developmental role for MBNL2 that might extend to other MBNL proteins. Specifically, the data point to the importance of *mbnl2* in muscle and brain development, which might help to unravel the DM phenotype: there is increasing evidence for central cognitive dysfunction in the disease. Furthermore, the data indicate that therapeutic strategies that aim to replace sequestered MBNL in the cells of DM patients should consider MBNL2 as well as MBNL1. Future experiments should assess the function of *mbnl1* and *mbnl3* during development, and determine how much of the phenotype observed in *mbnl2* morphant zebrafish is replicated in repeat expansion fish models.
